Motesanib
As of the edition of 20 October 2026, Motesanib is a small molecule: stopped in 2018; acts on FLT1, FLT4 and KDR and 3 more.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Stopped, 2018
- Kind
- Small molecule
- Registered trials
- 19, 7 stopped early
- Disease areas
- Cancer; Digestive system; Lungs and airways; Hormones; Skin and connective tissue; Blood and lymph
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
2 company-target rows on route B and 9 company-target rows on route A because of this drug.
Companies on route B for this drug
In the product2 company-target rows are on route B because of Motesanib.
See the 2 company-target rows on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Companies on route A for this drug
In the product9 company-target rows are on route A because of Motesanib.
See the 9 company-target rows on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Targets
| Gene | Protein | UniProt |
|---|---|---|
| PDGFRB | Platelet-derived growth factor receptor beta | P09619 |
| KIT | Mast/stem cell growth factor receptor Kit | P10721 |
| PDGFRA | Platelet-derived growth factor receptor alpha | P16234 |
| FLT1 | Vascular endothelial growth factor receptor 1 | P17948 |
| FLT4 | Vascular endothelial growth factor receptor 3 | P35916 |
| KDR | Vascular endothelial growth factor receptor 2 | P35968 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 8 | 6 | 0 | 1 |
| Phase 2 | 10 | 5 | 0 | 5 |
| Phase 3 | 1 | 0 | 0 | 1 |
| All trials | 19 |